US 2026/0148848 A1Published application

Biomarkers for diagnosis and treatment of endocrine hypertension, and methods of identification thereof

AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Université Paris Cité, University of Dundee, Radboud Umc, The University of Birmingham, University of Glasgow, UniversitäT ZüRich, Assistance Publique-Hopitaux de Paris

InventorsMaria-Christina ZENNARO, Laurence AMAR, Arlt WIEBKE, Felix BEUSCHLEIN, Eleanor DAVIES, Smarti REEL, Parminder Singh REEL, Emily JEFFERSON, Graeme EISENHOFER, Scott MACKENZIE, Alessandro PRETE, Angela TAYLOR, Jaap DEINUM

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma/Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).

Claims15

Dependent claims

A combination of biomarkers comprising at least:

(i-a) one biomarker selected in each of the following group of biomarkers:
Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers:
O-methylated catecholamines, Small metabolites, and miRNA;
(i-b) one biomarker selected in each of the following group of biomarkers:
Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers:
Patient's age, O-methylated catecholamines, and miRNA,
(i-c) one biomarker selected in each of the following group of biomarkers:
Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers:
Plasma steroids, Small metabolites, and miRNA,
(i-d) one biomarker selected in each of the following group of biomarkers:
Patient's age, Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers:
O-methylated catecholamines, and miRNA, or
(i-e) one biomarker selected in each of the following group of biomarkers:
O-methylated catecholamines, and at least one biomarker selected in at least one of the group of biomarkers:
Patient's age, Urinary steroids, and Small metabolites.

12 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/998,204Filed 28 Jul 2023
Priority: EP 22306151.629 Jul 2022
Published: 28 May 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

G16H 50/20
ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or…: for…
C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
G01N 33/6893
Involving proteins, peptides or amino acids: related to diseases not provided for elsewhere
G01N 33/743
Involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and…:…